Orphan drugs enter the market faster. Once a drug is approved for a decoy indication, labeled and off-label promotion may occur concurrently. Journal advertising and direct mail channels are used ...

New York–based drug giant Pfizer is paying $2.3 billion to settle claims of off-label promotion of four of its drugs, including the cyclooxygenase 2 (COX-2) inhibitor Bextra (valdecoxib), the US ...

"Before engaging in off-label promotion, companies should ascertain the risk profile, safety, efficacy, and potential commercial benefits of the use -- without committing that last bit to print".